Brace Team

 

Vinzenz Ploerer

President & CEO

 

Vinzenz Ploerer is Brace Pharma Capital’s President and CEO, and sits on the Board of Directors. Vinzenz has worked as a life science executive for over 20 years, and brings extensive leadership experience in operations, acquisitions and business development.

more...

Prior to launching Brace in 2013, he worked at EMS S/A as Senior Vice President of Strategy and Operations. He has also held multiple senior leadership positions at Novartis/Sandoz including various country head roles. Vinzenz currently sits on several corporate boards including GeNO, Therabron, Tyrogenex and Navitor. Vinzenz obtained his Masters of Business Administration from the University of Innsbruck.

less...

Daniel E. Salazar, Ph.D.

Vice President of Clinical & Regulatory

   

Daniel E. Salazar Ph.D. is Brace Pharma Capital’s Vice President of Clinical & Regulatory and is also the Chief Scientific Officer and member of the Board of Directors at EMS S/A.

more...

Dan has more than 25 years of experience in drug discovery, development, regulatory submissions and organizational leadership. He has made significant contributions to over 40 IND filings and 9 NDAs. He has co-authored over 80 publications and is an adjunct Associate Professor in the Department of Pharmaceutics at the University of Florida.

He was most recently Senior Vice President, Translational Medicine and Think Team at Otsuka Pharmaceutical Development. Dr. Salazar completed his undergraduate education at Princeton University where he majored in Biology and his Doctor of Pharmaceutical Science from the State University of New York at Buffalo.

less...

Todd Brady

Director of Finance & Investments

   

Todd Brady is the Director of Finance and Investments at Brace Pharma Capital. He also serves as a director for Brace portfolio companies GeNO LLC, Avidity Biosciences and Tyrogenex, and formerly served as a board observer for Miragen Therapeutics.

more...

Todd has an extensive and diverse background in Capital Markets, working in equity research, asset management, private equity and corporate banking over the duration of his career. Todd has a Masters of Business Administration from the Schulich School of Business (York University) and is a Chartered Financial Analyst (CFA).

less...

Basheer Zada, M.S.

Associate

    Basheer Zada is an Associate at Brace Pharma Capital. Prior to joining Brace, Basheer held various roles at Georgetown University's Office of Technology Commercialization, investment banking at Focus Investment Bankers and project management at a small pharmaceutical company. Basheer received his B.S. in Biology from Virginia Tech and his M.S. in Biotechnology from Georgetown University.

Pedro Bordeaux, M.S.

Associate

    Pedro Bordeaux is an Associate at Brace Pharma Capital. He also acts as a liaison between Brace and EMS. Previously, Pedro worked at EMS Pharma’s Intellectual Property Department where he was responsible of IP analysis, while leveraging his knowledge of Latin America IP Laws & Regulations. Prior to joining EMS, Pedro trained at the Friedrich Miescher Institute for Biomedical Research R&D Department. Pedro received his B.S. in Biology and M.S. Physiopathology from Unicamp (Campinas State University), Brazil.

Steven Saheb, M.S.

Associate

    Steven Saheb is an Associate at Brace Pharma Capital. Before joining Brace, Steven was employed at IMS Health, within their primary market research division. He also has experience working with the PBG Healthcare Consulting organization, run through the Wharton School of Business. Steven received his B.S. in Neurobiology and Physiology from the University of Maryland, College Park and his M.S. in Biotechnology from the University of Pennsylvania.

Camila Anglin

Office Manager

    Camila Anglin is an Office Manager at Brace Pharma Capital. Prior to joining Brace, Camila held multiple Accounting/HR Manager positions at the McFadyen Consulting Group, Sutter Health, Airbus Group, Sealed Air Inc, and Wings Telecom. Camila received her undergraduate degree at Faculdade Armando Alvares Penteado, Sao Paulo, Brazil. 
Venture Partners and Advisors

 

Eric I. Richman

Venture Partner

   

Eric I. Richman is a Venture Partner at Brace Pharma Capital. Eric has worked as a life science executive for over 20 years and brings significant leadership, operational and strategic experience.

more...

Prior to joining Brace, Eric served as President & CEO of PharmAthene. Previously, Eric was part of the founding team at MedImmune, where he was responsible for the U.S. launch of MedImmune’s first commercial product CytoGam®, and was an integral part of the global launch teams for marketed products including Synagis®.

He began his career at HealthCare Ventures, a Venture Capital firm focused on life sciences. Eric currently sits on several boards including Therabron, Tyrogenex, F2G (board observer), PharmAthene, ADMA Biologics and formerly was director of Lev Pharmaceuticals (sold to Viropharma) and American Bank (sold to Congressional Bancshares).

Eric completed his undergraduate education at the Sophie Davis School of Biomedical Education and earned his MBA from the American Graduate School of International Management.

less...

Samuel Broder, M.D.

Medical Advisor

   

Samuel Broder is the former head of the National Cancer Institute (NCI). President Ronald Reagan appointed Dr. Broder to serve as Director of the NCI in 1989, and he held the position for six years. While at the NCI, he also oversaw the development of numerous anti-cancer therapeutic agents, such as TAXOL®. 

more...

Dr. Broder joined the Celera Corporation at its founding in 1998, as the Executive Vice President for Medical Affairs and Chief Medical Officer, and helped advance the human genome project. His most recent position was as SVP, Health Sector, Intrexon Corp, with responsibilities for gene therapy and synthetic biology.

Dr. Broder spent his entire career in translational medicine.  His laboratory played a major role proving that it was, in fact, possible to treat HIV-1/AIDS by developing in short order the first 3 agents approved by FDA specifically to treat the AIDS virus. These are the novel nucleosides Retrovir® (AZT), Videx® (ddI), and HIVID® (ddC).

Dr. Samuel Broder graduated from the University of Michigan Medical School in Ann Arbor in 1970. He did an internship and residency in Internal Medicine at Stanford University in Palo Alto, and then did subspecialty training in medical oncology at the National Cancer Institute in Bethesda. He is the author or co-author of over 340 scientific publications, and is an inventor on many patents. He has received numerous scientific awards related to his research in cancer and AIDS.  He was elected to the National Academy of Medicine in 1993.

less...

Alan Cohen, M.D., FAAP, FCCP, FAAAAI, FACAAI

Medical Advisor

   

Dr. Alan H. Cohen is a board certified Pediatric Pulmonologist and presently the Senior Vice President & Chief Medical Officer (CMO) at Therabron Therapeutics.

more...

Alan has over 20 years of experience in drug development, medical affairs and organizational leadership contributing significantly to IND and NDA filings as well as post approval support of over 25 small molecule, biologic and vaccine therapies, globally. Prior to joining Therabron, Alan served as the CMO at Eddingpharm, Executive Director of Clinical Development & Medical Affairs at Boehringer Ingelheim, SVP of Medical Affairs at InterMune (now Genentech/Roche), and VP of Clinical Development and Medical Affairs at MAP Pharma (now Allergan).

Alan also served as CMO and VP of Global Medical Affairs at Jazz Pharma and began his drug development career as Senior Director of Medical Affairs at MedImmune (now AZ). Alan received his B.S. in Microbiology and B.A. in History at the University of Rochester and M.D. at New York Medical College. He completed his residency and fellowship at University of Colorado / National Jewish Center for Immunology and Respiratory Diseases.

Alan is currently an Adjunct Clinical Faculty member at Stanford University School of Medicine. He has held faculty appointments at Washington University, Emory University, Morehouse School of Medicine and Johns Hopkins School of Medicine.

less...